// Evidence Grader

Claim grades, A through F

Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.

A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
C
Adjuvant chemotherapy intensification based on ctDNA MRD improves overall survival
DFS signal in DYNAMIC; OS benefit not yet established. Active phase III work.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →
C
Multi-cancer early detection (MCED) tests like Galleri reduce cancer mortality in average-risk adults
Sensitivity for stage I disease modest (~17%); SYMPLIFY shows utility for symptomatic triage; mortality endpoint requires NHS-Galleri readout.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →